NOVO
Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged · TSX:NOVO
17.34 CAD0.2900 +1.70%
Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged (TSX:NOVO) last traded at 17.34 CAD, up 1.70% on the day. Over the past year the stock is down 17.39%. Its 52-week range is 14.88 to 27.58. It is in the Health Technology sector (Pharmaceuticals: Major).
Key statistics
Open17.37
Day range17.30 – 17.50
52-week range14.88 – 27.58
Volume14.94 K
Average volume (10 days)9.87 K
Market cap (USD)175.64 B
P/E3.06
EPS (TTM) (USD)3.99
Dividend yield4.40%
Beta (1 year)0.7215
Revenue (TTM) (USD)50.21 B
Employees68.79 K
Performance
+1.82%1 week
+5.99%1 month
−14.41%3 months
−3.99%6 months
−19.46%Year to date
−17.39%1 year
Technical rating
Buy
Daily summary of 11 oscillators and 15 moving averages. See every indicator
Latest headlines
- Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up NextStocktwits · 02 Nov 2026
- Jobs, Midterm Elections, Apple, Palantir, McDonald's, Moderna, and More to Watch This Week — Barrons.comDow Jones Newswires · 01 Nov 2026
- Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growthSeeking Alpha · 31 Oct 2026
- Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on CancerBenzinga · 29 Oct 2026
- Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026
- Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible (UPDATED)Benzinga · 28 Oct 2026
- LLY Vs NVO: Lilly’s Retatrutide Beats Novo’s Ozempic In Head-To-Head Trial — Retatrutide More Than Doubles Weight LossStocktwits · 28 Oct 2026
- Lilly's next-gen drug outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026
Market data from TradingView’s public feed, delayed as the exchange requires. For study only, not investment advice.